| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4188866 | Psiquiatría Biológica | 2006 | 7 Pages |
Abstract
Mirtazapine is an antidepressant with good efficacy and few adverse effects. This drug has also been reported to target symptoms of anxiety in depressed patients. The main mechanism for this efficacy is believed to be enhancement of both noradrenergic and serotonergic transmission. Due to the adverse effects commonly associated with the selective serotonin uptake inhibitors (SSRIs) and tetracyclic antidepressants (TCAs) used to treat panic disorder, mirtazapine has been used in some open trials. In the present article, we discuss the results of these studies, mainly those comparing mirtazapine with SSRIs (fluoxetine, paroxetine) in terms of efficacy and tolerability.
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
M. Teresa de Lucas Taracena, Francisco Montañés Rada,